Evidence map›Paper›PMID 34895278›Full record

ArticleDiagnostic pathology2021

Pancreatic medullary carcinoma developed on a pancreatic intraductal papillary mucinous neoplasm with loss of MSH2 and MSH6 expression: a case report.

Camille Verocq, Marie-Lucie Racu, Dominique Bafort, Gloria Butorano, Luis Perez-Casanova Garcia, Julie Navez, Marc Witterwulghe, Kieran Sheahan, Niall Swan, Jean Closset and 3 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Camille VerocqDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium. Camille.Verocq@erasme.ulb.ac.be.
Marie-Lucie RacuDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Dominique BafortCentre Universitaire Inter Régional d'Expertise en Anatomie Pathologique Hospitalière (CurePath), 6040, Charleroi, Belgium.
Gloria ButoranoCentre Universitaire Inter Régional d'Expertise en Anatomie Pathologique Hospitalière (CurePath), 6040, Charleroi, Belgium.
Luis Perez-Casanova GarciaDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Julie NavezDepartment of Hepato-Biliary-Pancreatic Surgery, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Marc WitterwulgheDepartment of Gastroenterology, CHIREC Hospitals, Delta, Brussels, Belgium.
Kieran SheahanDepartment of Pathology, UCD School of Medicine, St Vincent's University Hospital, Dublin, Ireland.
Niall SwanDepartment of Pathology, UCD School of Medicine, St Vincent's University Hospital, Dublin, Ireland.
Jean ClossetDepartment of Hepato-Biliary-Pancreatic Surgery, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Jean-Luc Van LaethemDepartment of Gastroenterology and Digestive oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Calliope MarisDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Nicky D'HaeneDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Université Libre de Bruxelles · BEGrand Charleroi Hospital · BESt. Vincent's University Hospital · IECentre Hospitalier Interrégional Edith Cavell · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic medullary carcinoma (PMC) is a rare pancreatic tumor, usually showing the presence of microsatellite instability, mostly MLH1 silencing, and a wild-type KRAS mutation status. We report here a PMC arising from a Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN), both having KRAS and TP53 mutations. CASE PRESENTATION: We report the case of a 73-year-old woman presenting with right iliac fossa pain. MRI revealed a 16 mm diameter mass in the pancreas, leading to a pancreatic duct stricture and upstream a dilatation of the distal pancreatic duct of Wirsung. A fine needle aspiration was performed, and pathology analysis revealed malignant glandular cells. The patient underwent distal pancreatectomy. Gross examination revealed an12 mm indurated white lesion, adjacent to a cystic lesion extending into the rest of the pancreatic body. Microscopically, the cystic area represented a mixed (gastric-type and pancreatobiliary-type) IPMN, involving the main and secondary pancreatic ducts with low-grade and high-grade dysplasia. In the periphery of this IPMN, a 14mm associated invasive carcinoma was observed, characterized by focal gland formation and by poorly differentiated cells with a syncytial appearance, associated with a dense lymphoplasmocytic and neutrophilic infiltrate. Immunohistochemical analyses showed loss of MSH2 and MSH6 expression. Microsatellite instability was confirmed by molecular test. Molecular analysis was performed both on the invasive carcinoma and on the high-grade dysplasia IPMN, revealing the same mutation profile with KRAS and TP53 mutations. The proposed diagnosis was mixed IPMN with associated invasive medullary carcinoma that presented loss of MSH2 and MSH6 expression.

conclusionsThe present case reports for the first time, at the best of our knowledge, the coexistence of IPMN lesions and PMC, both having the same molecular alterations. It also describes the second case of PMC with microsatellite instability, MSH2 and MSH6 silenced.

Indexed as

AgedBiomarkers, TumorCarcinoma, MedullaryDNA-Binding ProteinsDown-RegulationFemaleHumansMicrosatellite InstabilityMutationMutS Homolog 2 ProteinPancreatectomyPancreatic Intraductal NeoplasmsPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53Biomarkers, TumorDNA-Binding ProteinsG-T mismatch-binding proteinKRAS protein, humanMSH2 protein, humanMutS Homolog 2 ProteinProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53Case reportIntraductal papillary mucinous neoplasmIPMNMicrosatellite instabilityPancreatic medullary carcinoma

Identifiers

PMID34895278
PMCPMC8667442
OpenAlexW4200130298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.